Instem’s Post

The scientific community knows that accurate data representation is crucial for robust research outcomes. Yet, achieving true diversity in clinical trials has been a longstanding challenge. The Food and Drug Omnibus Reform Act (FDORA) is changing the game by mandating the prioritisation of representation in trials. Companies failing to meet these standards will face consequences. True patient representation is about to advance even further thanks to FDORA's incentives for businesses to act proactively in this area. Although I believe that diverse representation in clinical settings ought to have been implemented much earlier, the prospect of a truly diverse future is encouraging. #ClinicalResearch #DiversityInScience #FDORA #ClinicalTrials

In the final article of this series, Liam Eves and Kym Denny Eves explore how various drug candidates come inherent with barriers to adoption that directly impact how participants and providers engage with clinical research. https://lnkd.in/ePw3ah4u

Our CEO, Zachary Gobst, shared a few thoughts on the release of new guidance of Diversity Action Plans (DAPs) by the FDA. What are your thoughts on this new guidance? Share them in the comments below!

Transparency in RWE is long overdue and is essential to elevating the status of critical information gained from real world practice. A timely article here from Richard White and Alison Chisholm - are you ready to ride RWE transparency wave?

Great News in Clinical Trials! The FDA has just released new guidance on Diversity Action Plans (DAPs) aimed at improving the enrollment of underrepresented populations in clinical studies. This supports progress toward ensuring that clinical trials are more inclusive and reflective of our diverse society. At Leapcure, we are fully aligned with making a difference in this area. Our aim is to bring gravity to all voices and incorporate empathy with everyone—from patients and advocacy groups to research sites and sponsors—ensuring the most impactful medical breakthroughs. We look forward to collaborating with industry partners and the FDA to improve clinical trials. Together, we can lead the movement towards more inclusive, effective, and equitable clinical research. The latest guidance: https://lnkd.in/gAbQV4Ek #ClinicalTrials #DiversityInResearch #EquitableTrials #Leapcure #FDA #PatientCentricity #HealthcareInnovation

❓ Has the time come to expect of #RWE studies the same levels of #Transparency that are demanded of clinical trials? Read our latest guest blog from Richard White (COO at Oxford PharmaGenesis) and Alison Chisholm (Communications Team Leader at Oxford PharmaGenesis) to learn which way the tide is turning 🌊 #RealWorldEvidence #RealWorldData #RWD

Very interesting read on transparency in #RWE and the incredible value it has. Take a read!

Interesting approach about how to speed up #clinicaltrials reducing costs at the same time. My colleagues, experts in this area, could share how possible this would be, but it has been a huge necessity for many years that R+D haven't been able to solve. #clinicalresearch

What are the ✨ 7 most talked about factors with the potential to transform clinical trials? Read my article for Clinical Leader to find out! It is great when a project that I have been putting a lot of 👨🌾 effort into, starts giving back. The article below is based on the more than 🎧 80 interviews conducted on the show - and it aggregates the individual opinions to become actual data points. The vision of discovering what in fact can transform clinical trials is coming closer to grasp. #clinicaltrials #transformation #lifesciences https://lnkd.in/eXheBGxs

Speed up clinical trials with #syntheticdata 🚀